Literature DB >> 15728649

The variation of morphological and functional cardiac manifestation in Fabry disease: potential implications for the time course of the disease.

Frank Weidemann1, Frank Breunig, Meinrad Beer, Joern Sandstede, Stefan Störk, Wolfram Voelker, Georg Ertl, Anita Knoll, Christoph Wanner, Joerg M Strotmann.   

Abstract

AIMS: The aim of this clinical cross-sectional study was to investigate the cardiac interrelation of morphological and functional abnormalities in patients with Fabry disease. METHODS AND
RESULTS: Fifty-one patients (5-78 years) were compared with 25 controls (8-77 years). In all subjects, end-diastolic thickness of the left ventricle was measured by echocardiography and ultrasonic peak systolic strain rate (SR) was extracted to assess regional myocardial function. Magnetic resonance imaging was performed to assess late-enhancement for the detection of myocardial fibrosis in Fabry patients (n=39). In patients, women <20 years of age had no hypertrophy, no late-enhancement, and normal radial and longitudinal function (SR longitudinal=-1.7+/-0.5 s(-1); P=n.s. compared with controls). Ten women, >20 years of age, had no hypertrophy, no late-enhancement, normal radial and longitudinal function in the septal wall, but reduced longitudinal function in the lateral wall (SR=-1.4+/-0.5 s(-1)). All male patients without hypertrophy and no late-enhancement had normal radial function but reduced longitudinal function in both the septal and lateral walls (SR=-1.3+/-0.3 s(-1)). Patients with hypertrophy but without late-enhancement (n=13) had reduced radial and longitudinal function. Twelve patients displaying hypertrophy and late-enhancement had severely reduced radial and longitudinal function (SR=-1.1+/-0.5 s(-1)). Two of them with the worst impairment of regional function (SR=-0.8+/-0.6 s(-1)) died in the follow-up period.
CONCLUSION: These results illustrate the variation of morphological changes and its functional consequences in Fabry cardiomyopathy.

Entities:  

Mesh:

Year:  2005        PMID: 15728649     DOI: 10.1093/eurheartj/ehi143

Source DB:  PubMed          Journal:  Eur Heart J        ISSN: 0195-668X            Impact factor:   29.983


  57 in total

Review 1.  The role of echocardiographic deformation imaging in hypertrophic myopathies.

Authors:  Maja Cikes; George R Sutherland; Lisa J Anderson; Bart H Bijnens
Journal:  Nat Rev Cardiol       Date:  2010-05-11       Impact factor: 32.419

Review 2.  [Females with Fabry's disease - an interdisciplinary diagnostic and therapeutic challenge].

Authors:  Frank Weidemann; Markus Niemann; Claudia Sommer; Meinrad Beer; Frank Breunig; Christoph Wanner
Journal:  Med Klin (Munich)       Date:  2010-09-28

Review 3.  Cardiac magnetic resonance in myocardial disease.

Authors:  U Sechtem; H Mahrholdt; H Vogelsberg
Journal:  Heart       Date:  2006-06-06       Impact factor: 5.994

Review 4.  Use of tissue Doppler imaging to identify and manage systemic diseases.

Authors:  Frank Weidemann; Joerg M Strotmann
Journal:  Clin Res Cardiol       Date:  2007-08-29       Impact factor: 5.460

Review 5.  Identifying the etiology: a systematic approach using delayed-enhancement cardiovascular magnetic resonance.

Authors:  Annamalai Senthilkumar; Maulik D Majmudar; Chetan Shenoy; Han W Kim; Raymond J Kim
Journal:  Heart Fail Clin       Date:  2009-07       Impact factor: 3.179

Review 6.  Risks and diagnosis of coronary artery disease in Hodgkin lymphoma survivors.

Authors:  Serhan Kupeli
Journal:  World J Cardiol       Date:  2014-07-26

7.  Effects of switching from agalsidase Beta to agalsidase alfa in 10 patients with anderson-fabry disease.

Authors:  A Pisani; L Spinelli; B Visciano; I Capuano; M Sabbatini; E Riccio; G Messalli; M Imbriaco
Journal:  JIMD Rep       Date:  2012-10-21

8.  Normal left-atrial structure and function despite concentric left-ventricular remodelling in a cohort of patients with Anderson-Fabry disease.

Authors:  Brendan N Putko; Haran Yogasundaram; Kelvin Chow; Joseph Pagano; Aneal Khan; D Ian Paterson; Richard B Thompson; Gavin Y Oudit
Journal:  Eur Heart J Cardiovasc Imaging       Date:  2015-03-06       Impact factor: 6.875

Review 9.  [Pain therapy for Fabry's disease].

Authors:  C Sommer; N Uçeyler; T Duning; K Arning; R Baron; E Brand; S Canaan-Kühl; M Hilz; D Naleschinski; C Wanner; F Weidemann
Journal:  Internist (Berl)       Date:  2013-01       Impact factor: 0.743

10.  Fabry disease in children and the effects of enzyme replacement treatment.

Authors:  Guillem Pintos-Morell; Michael Beck
Journal:  Eur J Pediatr       Date:  2009-02-26       Impact factor: 3.183

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.